Intrepid Capital Management Inc. raised its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 18.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,979 shares of the medical research company’s stock after buying an additional 630 shares during the quarter. Intrepid Capital Management Inc.’s holdings in Bio-Rad Laboratories were worth $1,216,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds also recently made changes to their positions in BIO. Tower House Partners LLP purchased a new stake in Bio-Rad Laboratories during the 4th quarter valued at approximately $52,249,000. Norges Bank purchased a new stake in Bio-Rad Laboratories during the 4th quarter valued at approximately $46,327,000. First Trust Advisors LP grew its holdings in Bio-Rad Laboratories by 82.2% during the 4th quarter. First Trust Advisors LP now owns 186,624 shares of the medical research company’s stock valued at $43,338,000 after buying an additional 84,187 shares in the last quarter. Intermede Investment Partners Ltd purchased a new stake in Bio-Rad Laboratories during the 4th quarter valued at approximately $18,902,000. Finally, BlackRock Inc. grew its holdings in Bio-Rad Laboratories by 3.6% during the 4th quarter. BlackRock Inc. now owns 1,936,008 shares of the medical research company’s stock valued at $449,580,000 after buying an additional 68,124 shares in the last quarter. 64.34% of the stock is owned by institutional investors and hedge funds.
In related news, EVP Timothy S. Ernst sold 345 shares of the firm’s stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $290.00, for a total value of $100,050.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 27.84% of the company’s stock.
Shares of BIO stock traded up $1.78 on Friday, reaching $300.53. The company’s stock had a trading volume of 33,588 shares, compared to its average volume of 162,341. Bio-Rad Laboratories, Inc. has a 1 year low of $220.05 and a 1 year high of $345.15. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.24 and a current ratio of 4.57. The firm has a market cap of $8.86 billion, a PE ratio of 51.46, a price-to-earnings-growth ratio of 2.77 and a beta of 1.22.
Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Wednesday, May 8th. The medical research company reported $1.65 earnings per share for the quarter, beating analysts’ consensus estimates of $1.12 by $0.53. Bio-Rad Laboratories had a net margin of 24.84% and a return on equity of 4.15%. The firm had revenue of $553.98 million during the quarter, compared to analyst estimates of $548.82 million. On average, equities analysts predict that Bio-Rad Laboratories, Inc. will post 7.15 EPS for the current year.
A number of brokerages have issued reports on BIO. Zacks Investment Research lowered shares of Bio-Rad Laboratories from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 1st. ValuEngine raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, May 9th. Deutsche Bank increased their price objective on shares of Bio-Rad Laboratories from $350.00 to $375.00 and gave the company a “buy” rating in a report on Thursday, May 9th. Finally, Barclays increased their price objective on shares of Bio-Rad Laboratories from $340.00 to $350.00 and gave the company an “overweight” rating in a report on Thursday, May 9th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $365.00.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by Riverton Roll and is the property of of Riverton Roll. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://rivertonroll.com/news/2019/06/14/bio-rad-laboratories-inc-nysebio-shares-bought-by-intrepid-capital-management-inc.html.
Bio-Rad Laboratories Profile
Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.
Featured Story: How to interpret the current ratio
Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.